Literature DB >> 1322988

Probes for narcotic receptor mediated phenomena. 18. Epimeric 6 alpha- and 6 beta-iodo-3,14-dihydroxy-17-(cyclopropylmethyl)-4,5 alpha-epoxymorphinans as potential ligands for opioid receptor single photon emission computed tomography: synthesis, evaluation, and radiochemistry of [125I]-6 beta-iodo-3,14-dihydroxy-17-(cyclopropylmethyl)-4,5 alpha-epoxymorphinan.

B R de Costa1, M J Iadarola, R B Rothman, K F Berman, C George, A H Newman, A Mahboubi, A E Jacobson, K C Rice.   

Abstract

The epimeric 6 beta- and 6 alpha-iodo-3,14-dihydroxy-17-(cyclopropylmethyl)-4,5 alpha-epoxymorphinans (1, ioxy) and (2, epioxy), respectively, were each synthesized in five steps starting with naltrexone. The configuration of the 6-iodo group of 1 was unequivocally determined to be beta-based on single crystal X-ray analysis of its precursor 3-acetoxy-6 beta-iodo-14-hydroxy-17-(cyclopropylmethyl)-4,5 alpha-epoxymorphinan (10). Both 1 and 2 as well as their corresponding 3-O-acetates 10 and 11 were found to readily cross the blood-brain barrier and completely reverse the analgesic effects of a 10 mg/kg intraperitoneal dose of morphine sulfate as determined by the paw withdrawal latency test. Compounds 1 and 2 were found to bind with high affinity to mu, delta, and kappa receptors in vitro. In general, 1 and 2 exhibited higher affinity for mu and kappa receptors than naltrexone while the 6 beta-iodo epimer 1 (ioxy) was more potent than its epimer 2. In a comparison of the 6 beta-halogen substituent on binding affinity across opioid receptor subtypes, it was generally found that I greater than Br greater than F. On the basis of the results of in vitro and in vivo testing, 1 was selected as a target for radioiodination and evaluation as a potential single photon emission computed tomography imaging agent for opioid receptors. Carrier-free [125I]-1 was synthesized in near quantitative yield by the sequence of reaction of excess 3-acetoxy-6 alpha-[[(trifluoromethyl)sulfonyl]oxy]-14-hydroxy-17- (cyclopropylmethyl)-4,5 alpha-epoxymorphinan (8) with anhydrous Na125I in dry acetonitrile for 90 min at 76 degrees C followed by deacetylation of the product with 1:1 aqueous ammonia/acetonitrile at 25 degrees C. The potential of [125I]-1 as an in vivo imaging agent for opioid receptors is evaluated and discussed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1322988     DOI: 10.1021/jm00093a016

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  7 in total

1.  Synthesis and in vitro stability of amino acid prodrugs of 6-β-naltrexol for microneedle-enhanced transdermal delivery.

Authors:  Joshua A Eldridge; Mikolaj Milewski; Audra L Stinchcomb; Peter A Crooks
Journal:  Bioorg Med Chem Lett       Date:  2014-10-02       Impact factor: 2.823

2.  Structure-Activity Relationships of (+)-Naltrexone-Inspired Toll-like Receptor 4 (TLR4) Antagonists.

Authors:  Brandon R Selfridge; Xiaohui Wang; Yingning Zhang; Hang Yin; Peter M Grace; Linda R Watkins; Arthur E Jacobson; Kenner C Rice
Journal:  J Med Chem       Date:  2015-06-05       Impact factor: 7.446

3.  Herkinorin analogues with differential beta-arrestin-2 interactions.

Authors:  Kevin Tidgewell; Chad E Groer; Wayne W Harding; Anthony Lozama; Matthew Schmidt; Alfred Marquam; Jessica Hiemstra; John S Partilla; Christina M Dersch; Richard B Rothman; Laura M Bohn; Thomas E Prisinzano
Journal:  J Med Chem       Date:  2008-04-02       Impact factor: 7.446

4.  Flux across [corrected] microneedle-treated skin is increased by increasing charge of naltrexone and naltrexol in vitro.

Authors:  Stan L Banks; Raghotham R Pinninti; Harvinder S Gill; Peter A Crooks; Mark R Prausnitz; Audra L Stinchcomb
Journal:  Pharm Res       Date:  2008-05-01       Impact factor: 4.200

5.  Reinforcing effects of sigma-receptor agonists in rats trained to self-administer cocaine.

Authors:  Takato Hiranita; Paul L Soto; Gianluigi Tanda; Jonathan L Katz
Journal:  J Pharmacol Exp Ther       Date:  2009-11-05       Impact factor: 4.030

6.  Dihydrocodeinone-hydrazone, dihydrocodeinone-oxime, naloxone-3-OMe-oxime, and clocinnamox fail to irreversibly inhibit opioid kappa receptor binding.

Authors:  Q Ni; H Xu; J S Partilla; B R de Costa; K C Rice; A Borsodi; S Hosztafi; R B Rothman
Journal:  Neurochem Res       Date:  1994-09       Impact factor: 3.996

7.  Transdermal delivery of naltrexol and skin permeability lifetime after microneedle treatment in hairless guinea pigs.

Authors:  Stan L Banks; Raghotham R Pinninti; Harvinder S Gill; Kalpana S Paudel; Peter A Crooks; Nicole K Brogden; Mark R Prausnitz; Audra L Stinchcomb
Journal:  J Pharm Sci       Date:  2010-07       Impact factor: 3.534

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.